Can a new cosmetic pass the skin allergy test?

NCT ID NCT07797192

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial checks whether the cosmetic product Blancy Pro causes skin irritation, allergic reactions, or sensitivity to sunlight. About 55 healthy adults will have the product applied to their skin repeatedly, with some areas exposed to ultraviolet light. Doctors will grade any skin reactions using a standard scale. The goal is to see if the product is safe for people to use on their skin.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blancy Pro, a cosmetic product applied to the skin
What this could lead to
If the product passes, it could be confirmed as safe for regular use on skin, including sun-exposed areas.
What could go wrong
The trial is small and only checks skin reactions, not long-term effects. Some people may still develop irritation or allergies despite the results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female participants aged 18 to 70 years. * Fitzpatrick skin phototypes I, II, III, or IV. * Intact skin at the application site. * Willingness to comply with all study procedures and attend scheduled clinic visits for medical assessments, patch applications, and patch readings. * Ability to understand the study requirements, provide written informed consent, and sign the Informed Consent Form (ICF). For the phototest procedure, only participants with Fitzpatrick skin phototypes II and III will be eligible. Exclusion Criteria: * Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study. * Use of anti-inflammatory medications within 30 days prior to screening or immunosuppressive medications within 3 months prior to screening. * Immunosuppression due to medication use or active disease. * Uncontrolled endocrine disorders. * Personal history of atopy. * Intense sun exposure or tanning sessions within 15 days prior to assessment or during the study period. * Planned intense sun exposure or tanning sessions during the study period. * Planned sea bathing, swimming pool use, or sauna sessions during the study period. * Participation in water sports during the study period. * Dermographism. * Use of oral or topical vitamin A acid (retinoids) or related derivatives within 1 week prior to study initiation. * Aesthetic and/or dermatological body treatments within 3 weeks prior to screening. * Scheduled vaccination during the study period or within 3 weeks prior to screening. * History of sensitization, irritation, or photosensitization to topical products. * Active local or generalized skin diseases that may interfere with study assessments. * Skin hyperreactivity. * Initiation of new medications during the study period. * Previous participation in studies involving the same investigational product. * Congenital or acquired immunodeficiency. * Relevant medical history or current evidence of alcohol or substance abuse. * Known or suspected intolerance to any ingredient contained in the investigational or comparator products. * History of poor compliance or unwillingness to comply with the study protocol. * Employees of the study site, sponsor, or their immediate family members directly involved in the study. * Any other condition that, in the investigator's opinion, may interfere with study participation or justify exclusion from the study. Additional Exclusion Criteria for the Phototest: * History of diseases aggravated or triggered by ultraviolet radiation. * Use of photosensitizing medications. * History or current presence of photodermatoses. * Personal or family history of skin cancer. * Presence of precancerous skin lesions, including melanocytic nevi or actinic keratoses, that may interfere with study assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAFETY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Grupo Medcin

    RECRUITING

    Osasco, São Paulo, 06023-070, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.